Member Info for Lutra

Offgrid, while your comment about one-off treatments versus daily treatments may seem to make sense, in practice, a private veterinarian (especially in the USA) will almost always recommend in favour of the recurrent fee over the one-off charge. The highly effective canine hookworm vaccine in the US failed because routine worm treatment didn't just provide ongoing drug-sales income for vets but also a regular visit to the surgery where they could charge a check-up fee and "upsell" other treatments, services and diagnostics.

I'm afraid BSIF, alienated me with the following phrase in today's RNS:

"In addition, BSIF Shareholders will be entitled to keep the second interim dividend of 2.25 pence per BSIF Share payable to qualifying BSIF Shareholders on or around 15 June 2026 (the "Permitted Dividend"). "

That was a payment that they had already declared and which we were already legally entitled to - it went ex-Div on the 21st May. It's not something that they are giving us out of the kindness of their hearts!

Hey! I'm back in the black on ITM for the first time in a very long time! Alphabetically, my portfolio used to read HSBC then ITM and at that time the two share prices were neck and neck. Currently we are at £13.80 for HSBA and £1.80 for ITM...!

Interesting article in the NY Times today about the market in US for dog-longevity treatments. No mention of Geneflow, but interesting to see what else is happening in this part of the pet market. The article is at https://www.nytimes.com/2026/05/09/magazine/dog-longevity-treatments.html I'm not sure if it is pay-wall protected, but I think NY Times allows a limited number of free articles.

Yes, I got everything I asked for. I'm not sure if I was below some sort of scaling threshold or if they were undersubscribed?

This is one area where I feel HL's processes are unhelpful. They added the value of the offer shares to the portfolio, regardless of whether you have opted to take the offer up. They don't deduct the offer cost (or the value of any additional shares that you bid for) from the cash shown or the portfolio value. It all just seems to lack consistency to me, but fine as long as you understand what they are doing.

You could at least tell us what the lucky share was! :)

Yep! Me too. Bought in to this one for the first time this morning at opening, but my 250k shares are showing as a sell.

Can anyone point me in the direction of the base value for tax purposes of the MICC shares at the demerger?

Dibbs, at the moment, though HICL is down about 6p on the news, so you may want to re-do your calculation!

The RNS is good news, but it needs to be taken with a healthy level of caution. In the real world, Patents are open to challenge, particularly if there is any previous leak of the technology, making it "prior art". The patentable aspects are often technical aspects rather than the idea itself and ways can often be found to achieve the same thing by other routes. Small companies rarely have the deep pockets to challenge patent violation by the big guys.

Also, a biomedical patent is, at best, a 17 -year protection - dated from first publication of the the technology. The process of turning the research into a product eats up a lot of that patent period, which is why the big companies don't patent until they are much further on in the product development cycle than GENF seems to be. It is the problem most start-ups have - to get investment they need to show that they have a product, which means either patenting early or risking "prior art" by publicising their research.

As I say, it is good news but not transformative.

Ripley, charting doesn't work when the outlook for a company becomes binary - it's either going to survive or liquidate and no amount of past data can predict that future.

For a proper comparison, you need to include the energy used to make ammonia in the first place. Your 9.5kWh for the cracker is only half of the energy cost. If you add in a possible 10-12kWh for making the ammonia, the comparison would be somewhere in the 20-22kWh per Kg of Hydrogen - still less than 37kWh but by a smaller margin.

Deutscher, LSE works well for me on Opera. I'm on a Linux machine, though (Ubuntu, Noble Numbat).

Oldtramp, it will be interesting to see how the discussion at committee goes. The previous recommendation was also to not raise any objection. Some Councillors will be very tempted to pass the political buck, by maintaining their objection and forcing a public inquiry.

The waters may also be muddied by the fact that the adjacent Hill of Rifiga BESS application is later on the same Agenda. While Planners and Committee have to view each application individually on its merits, Councillors and Communities naturally look more to cumulative effects.

With a major grid connection, grid strengthening and a lot of local renewables generation, it is highly likely that the 2020 scoping application for a data centre on this site will move forward, once there is sufficient BESS capacity available to ensure emergency operability. I am pretty sure that Ministers understand that this is a major development site of national strategic importance, so I remain confident that it will eventually be approved.

Is the debt not covered by the potential Taiwan sale, with any offer for the rest of the company then attributable to shareholders (net of costs)?

Perhaps, Rob, but this is an unusual quandry - technology too important to let the Chinese have it, but Company too broke to continue... I could see a new Government grant/loan coming through to kick the can down the road for another few months.

aat****z, to be fair the hydropulse section needs to be taken seriously and has not been emphasised before. it is both good news and bad - "technology risk mitigation for the end user" means technology risk acceptance for itm!

Speak for yourself, YOrke926! I'm currently up 22% on SAE!

...well, big in VRS terms! Small in the greater scheme of things!